Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
Details
Publication Year 2021-11,Volume 13,Issue #22,Page 5810
Journal Title
Cancers
Publication Type
Review
Abstract
Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non-genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post-transcriptional and metabolic reprogramming. A growing body of evidence highlights the inherent plasticity of melanoma metabolism, evidenced by reversible metabolome alterations and flexibility in fuel usage that occur during metastasis and response to anti-cancer therapies. Here, we discuss how the inherent metabolic plasticity of melanoma cells facilitates both disease progression and acquisition of anti-cancer therapy resistance. In particular, we discuss in detail the different metabolic changes that occur during the three major phases of the targeted therapy response-the early response, drug tolerance and acquired resistance. We also discuss how non-genetic programs, including transcription and translation, control this process. The prevalence and diverse array of these non-genetic resistance mechanisms poses a new challenge to the field that requires innovative strategies to monitor and counteract these adaptive processes in the quest to prevent therapy resistance.
Department(s)
Laboratory Research; Medical Oncology
PubMed ID
34830962
Open Access at Publisher's Site
https://doi.org/10.3390/cancers13225810
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-05-23 04:02:52
Last Modified: 2025-05-23 04:04:10

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙